Cost Analysis and Treatment of Covid-19 Patients with Comorbidities at Rspad Gatot Soebroto

Authors

  • Petrus Kabul Togarma Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Pancasila, Jakarta, Indonesia
  • Yusi Anggriani Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Pancasila, Jakarta, Indonesia
  • Hesty Utami R Fakultas Farmasi Universitas Pancasila, Jakarta, Indonesia
  • Dewiyana Andari K RSPAD Gatot Soebroto, Jakarta, Indonesia

DOI:

https://doi.org/10.59188/eduvest.v4i9.3794

Keywords:

Cost; Treatment; Covid-19; Severity; Outcomes

Abstract

The COVID-19 pandemic has significantly affected the global health sector, especially in patients with comorbidities such as type-2 diabetes mellitus and hypertension. Patients with these comorbidities require special attention and proper handling during the COVID-19 treatment process, given the higher risk of complications in this group. Gatot Soebroto Army Hospital, as a referral center for COVID-19 in Indonesia, faces the complexity of handling patients who often have complicated clinical conditions which are also related to the costs required. Therefore, analyzing the cost and treatment of COVID-19 patients who also suffer from comorbidities such as hypertension, type-2 diabetes mellitus, type-2 diabetes mellitus and hypertension is essential to improve care management. This study took place from January to July 2021 at Gatot Soebroto Army Hospital. The purpose of the study was to determine the cost and treatment of COVID-19 and the relationship between severity and outcomes. The method used was retrospective observational in COVID-19 patients with these comorbidities. The results showed that the largest cost expenditure came from room and accommodation costs. The highest average total cost came from a combination of comorbid hypertension and type-2 DM. The frequently used treatment profile showed antiviral therapy (favipirapir), antibiotics (Levofloxacin and Azithromycin), anticoagulants (heparin), corticosteroids (dexamethasone), and symptomatic (paracetamol). Improvement in clinical condition was the highest clinical outcome. The result of Chi-Square test analysis between severity and clinical outcome was significant (p-value 0.007<0.05). In conclusion, the treatment profile is adjusted to the clinical condition and the severity of COVID-19 affecting the clinical outcome.

References

Aseng, C. R., Wiyono, W. I., & Jayanti, M. (2023). Evaluation Of Antibiotic Use In Covid-19 Patients At Rsup Prof . Dr . R . D . Kandou Manado Period January-March 2021. 12(March 2021), 77–82.

Ayu., W. W., Utami, H., Anggriani, Y., & Haryani, S. (2022). Analisis Perbandingan Biaya Riil Dengan Tarif Klaim Cost Per Day Dan Outcome Klinis Pada Pasien COVID-19 Dengan Komorbid Hipertensi Dan Diabetes Melitus Di RSUP Fatmawati. 7(2), 75–86.

Burhan, E., Dwi Susanto, A., Nasution, S. A., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N. G., Adityaningsih, D., Fahrial Syam, A., Rasmin, M., Rengganis, I., Sukrisman, L., Damayanti, T., Heru Wiyono, W., Isbaniah, F., … Mayung Sambo, C. (2020). Pedoman Tatalaksana COVID-19 Edisi 3 (E. Burhan, A. D. Susanto, & F. Isbaniah (eds.)). PDPI, PERKI, PAPDI, PERDATIN, IDAI.

Cartika, H., Cartika, H., Yusmaniar, Y., Hakim Kurniawan, A., Hasbi, F., & Suryani, D. (2022). Profile of Prescribing COVID -19 Drug Therapy in Inpatients At Jakarta Haji Hospital. SANITAS: Jurnal Teknologi Dan Seni Kesehatan, 13(1), 1–12. https://doi.org/10.36525/sanitas.2022.1

Djaharuddin, I., Munawwarah, S., Nurulita, A., Ilyas, M., Tabri, N. A., & Lihawa, N. (2021). Comorbidities and mortality in COVID-19 patients. Gaceta Sanitaria, 35(January), S530–S532. https://doi.org/10.1016/j.gaceta.2021.10.085

Giusman, R., & Nurwahyuni, A. (2022). Biaya Pengobatan Pasien Rawat Inap Covid-19 Di Rumah Sakit X Tahun 2021. Jurnal Ekonomi Kesehatan Indonesia, 7(2), 96. https://doi.org/10.7454/eki.v7i2.5797

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., Iotti, G., Latronico, N., Lorini, L., Merler, S., Natalini, G., Piatti, A., Ranieri, M. V., Scandroglio, A. M., Storti, E., … Pesenti, A. (2020). Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA - Journal of the American Medical Association, 323(16), 1574–1581. https://doi.org/10.1001/jama.2020.5394

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, S. I., Kim, L., Tong, S., Lu, X., Lindstrom, S., … Pillai, S. K. (2020). First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine, 382(10), 929–936. https://doi.org/10.1056/nejmoa2001191

Kementrian Kesehatan Republik Indonesia. (2020). Pedoman dan Pencegahan Coronavirus (COVID- 19). Pedoman Dan Pencegahan Coronavirus (COVID-19) Revisi 5, 5, 1–214.

Liang, X., Shi, L., Wang, Y., Xiao, W., Duan, G., Yang, H., & Wang, Y. (2020). The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates. Journal of Infection, 81(3), e44–e47. https://doi.org/10.1016/j.jinf.2020.06.060

Lv, M., Luo, X., Estill, J., Liu, Y., Ren, M., Wang, J., Wang, Q., Zhao, S., Wang, X., Yang, S., Feng, X., Li, W., Liu, E., Zhang, X., Wang, L., Zhou, Q., Meng, W., Qi, X., Xun, Y., … Wang, X. (2020). Coronavirus disease (COVID-19): A scoping review. In Eurosurveillance (Vol. 25, Issue 15). European Centre for Disease Prevention and Control (ECDC). https://doi.org/10.2807/1560-7917.ES.2020.25.15.2000125

Medis, B., Klaim, K., Cbg, T. I.-, Covid-, P., Anutapura, R. S. U., Tandah, M. R., Diana, K., Adisaputra, A. D., & Monica, S. (2023). Direct Medical Costs and Accordance of INA-CBG ’ s Claims on Covid-19 Patients at Anutapura Hospital. 9(1), 71–83. https://doi.org/10.22487/j24428744.2023.v9.i1.16085

Nugraha, R. R., Pratiwi, M. A., Al-Faizin, R. E., Permana, A. B., Setiawan, E., Farianty, Y., Komaryani, K., & Thabrany, H. (2022). Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020-2021. Health Economics Review, 12(1), 1–10. https://doi.org/10.1186/s13561-022-00392-w

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., Barnaby, D. P., Becker, L. B., Chelico, J. D., Cohen, S. L., Cookingham, J., Coppa, K., Diefenbach, M. A., Dominello, A. J., Duer-Hefele, J., Falzon, L., Gitlin, J., Hajizadeh, N., Harvin, T. G., … Zanos, T. P. (2020). Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - Journal of the American Medical Association, 323(20), 2052–2059. https://doi.org/10.1001/jama.2020.6775

Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, 109. https://doi.org/10.1016/j.jaut.2020.102433

Downloads

Published

2024-09-24

Issue

Vol. 4 No. 9 (2024): Journal Eduvest - Journal of Universal Studies

Section

Articles

License

Copyright (c) 2024 Petrus Kabul Togarma, Yusi Anggriani, Hesty Utami R, Dewiyana Andari K

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.